Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helicobacter pylori eradication and glycemic control in type 2 diabetes
IRCT20220920056004N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of bismuth subsalicylate, metronidazole, amoxicillin and omeprazole in Helicobacter pylori infection (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoints: Blood sugar control, Fasting blood sugar change and 1 more. Started Dec 2022; status: completed.
02
Drugs
bismuth subsalicylatemetronidazoleamoxicillinomeprazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20220920056004N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220920056004N1.